Illumina Expands Collaboration With Janssen Research & Development To Advance Molecular Residual Disease Cancer Test
Portfolio Pulse from Benzinga Newsdesk
Illumina is expanding its collaboration with Janssen Research & Development, a division of Johnson & Johnson, to advance the development of its Whole Genome Sequencing (WGS) Molecular Residual Disease (MRD) assay. This collaboration aims to enhance the utility of Illumina's WGS MRD test in cancer treatment by working with leading pharmaceutical companies.
January 05, 2024 | 2:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Illumina is expanding its collaboration with Janssen to advance its WGS MRD cancer test, which could lead to increased adoption and revenue growth.
The expanded collaboration with Janssen is likely to enhance the development and utility of Illumina's WGS MRD assay. This could result in increased adoption of the test in clinical settings, leading to potential revenue growth for Illumina in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Johnson & Johnson, through its Janssen division, is collaborating with Illumina to advance a cancer test, which may enhance Janssen's oncology portfolio.
The collaboration with Illumina to develop the WGS MRD assay aligns with Janssen's focus on oncology and could bolster its portfolio in this area. This may have a positive impact on JNJ's stock in the short term as it demonstrates commitment to advancing cancer treatment.
CONFIDENCE 80
IMPORTANCE 65
RELEVANCE 60